Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])

(2016) Bruce E. Strober et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2015) Richard B. Warren et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

(2014) Christopher Ritchlin et al.   ANNALS OF THE RHEUMATIC DISEASES

‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network

(2014) J.M.P.A. van den Reek et al.   BRITISH JOURNAL OF DERMATOLOGY

Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis

(2014) S.P. Menting et al.   BRITISH JOURNAL OF DERMATOLOGY

Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

(2014) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY

Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)

(2014) A.B. Kimball et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis

(2014) Zhun Cao et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry

(2014) J.M.P.A. van den Reek et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

(2013) P J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study

(2013) M. Esposito et al.   BRITISH JOURNAL OF DERMATOLOGY

Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre

(2013) A. López-Ferrer et al.   BRITISH JOURNAL OF DERMATOLOGY

Antidrug antibodies in psoriasis: a systematic review

(2013) L. Hsu et al.   BRITISH JOURNAL OF DERMATOLOGY

Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis

(2013) J.M.P.A. van den Reek et al.   BRITISH JOURNAL OF DERMATOLOGY

Biologic fatigue in psoriasis

(2013) Ethan C. Levin et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting

(2013) Machaon Bonafede et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Drug survival rates in patients with psoriasis after treatment with biologics

(2013) Yoshinori Umezawa et al.   JOURNAL OF DERMATOLOGY

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis

(2012) Howa Yeung et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

(2011) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab in clinical practice: response depends on dose and previous treatment

(2011) V. Ruiz Salas et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris

(2010) A. Clemmensen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

(2010) Martin Rudwaleit et al.   ARTHRITIS RESEARCH & THERAPY